Study of Aerovanc for the Treatment of Persistant MRSA Lung Infections in CF Patients

Trial Name

Study of Aerovanc for the Treatment of Persistant MRSA Lung Infections in Cystic Fibrosis (CF) patients

What is the trial about?

The purpose of this research study is to evaluate the effectiveness and safety of AeroVanc compared to placebo (an inactive substance that looks like the study drug) in people with CF and a chronic MRSA lung infection. 

Who can participate?

Males and females six years of age and older with confirmed history of cystic fibrosis and chronic MRSA.

What is involved?

Participation in this study will last up to 54 weeks and will include 13 study visits to the study center. This study has two periods. Period 1 will last up to 28 weeks (including Screening) and have nine visits; Period 2 will last up to 24 weeks but will only have four visits. 

Blood draws will occur on nine of the scheduled visits. Other procedures include PFT spirometry, ECG, vital signs, physical exam, sputum collection, mucus collection for cultures, completion of diaries and questionnaires and urinalysis.